Introduction
Atherosclerosis is a chronic inflammatory disease within the intima of large-and medium-sized arteries. Accumulation of lipids and an ensuing persistent inflammatory response leads to a gradual formation of atherosclerotic plaques, which ultimately develop to complex lesions. 1 The stability of lesions is a critical factor affecting the development of complications. Advanced fibroatheroma plaques that have large necrotic core and thin fibrous cap with infiltrated inflammatory cells in the shoulder region are unstable and prone to rupture, predisposing to myocardial infarction (MI), stroke, and sudden death. 2, 3 Oxidative stress, an imbalance between the production and disposal of reactive oxygen species (ROS), contributes to atherogenesis and formation of unstable atherosclerotic lesions. 4 Low-density lipoprotein (LDL) particles entrapped in the arterial intima are modified by ROS, evoking activation of macrophages, endothelial cells, and smooth muscle cells to produce pro-inflammatory cytokines, leading to atherosclerotic lesion progression and chronic inflammation. 5, 6 The balance between the formation and disposal of ROS is maintained by antioxidant genes that can be regulated in an integrated manner by the transcription factor nuclear factor E2-related factor 2 (Nrf2), which is responsive to both environmental factors and endogenous stimuli. Nrf2 is ubiquitously expressed in vascular cells, and it regulates several antioxidant enzymes providing cytoprotection in the vasculature. Many of them, such as haeme oxygenase-1, glutathione reductase, and peroxiredoxin-1 and -2, have been shown to be atheroprotective in atherosclerotic mouse models. [7] [8] [9] [10] Nrf2 regulates antioxidant gene expression in vascular cells after exposure to modified LDL 11 and oxidized phospholipids in vivo 12 in the carotid artery, and it is activated by laminar shear stress in vitro 13 as well as in vivo.
14 Adenoviral Nrf2 gene transfer inhibits vascular inflammation and oxidative stress in a rabbit angioplasty model. 15 Moreover, Nrf2 deficiency in bone marrow-derived macrophages aggravates atherosclerosis in LDLR -/-mice, supporting the notion that Nrf2 is atheroprotective in the vascular wall. 11, 16 Contradictory to the antioxidant and anti-inflammatory effects of Nrf2, global Nrf2 deficiency alleviates atherosclerosis in hypercholesterolaemic ApoE -/-mice. [17] [18] [19] [20] The mechanisms by which Nrf2 mediates its proatherogenic action in this model is currently unknown, but combined systemic and local vascular effects have been suggested. Nrf2 deficiency has been shown to decrease plasma total cholesterol on a regular chow or on a high-fat diet (HFD) in ApoE -/-mice in some 18, 19 but not in all studies. 17, 20 ApoE -/-mice are widely used in the field of atherosclerosis research, but their plasma lipoprotein profiles only poorly recapitulate that of human hypercholesterolaemia. ApoE -/-mice have certain shortcomings in modelling human atherosclerosis as they have a nonphysiological lipoprotein profile consisting mainly of VLDL and chylomicron remnants that have apoB-48 as the major apolipoprotein. Moreover, apoE has direct functions in the vessel wall as it facilitates cholesterol efflux from macrophage foam cells, and directly modifies macrophage-and T lymphocyte-mediated immune responses thereby affecting vascular inflammation. [21] [22] [23] [24] In the LDLR -/-ApoB 100/100 mouse model, the apoB-100 mRNA tissue-specific RNA editing is blocked and only apoB-100 protein is produced resulting in a more human-like hypercholesterolaemia even on a regular chow diet. [25] [26] [27] LDLR -/-mice on the other hand exhibit only a modest increase in plasma LDL cholesterol on a regular chow diet, and they do not develop significant lesions unless fed HFD.
28
Nrf2 has protective functions via regulation of antioxidant and antiinflammatory genes, and thus it is a promising drug target for the treatment of chronic inflammatory diseases. Given that oxidative stress and inflammation has been implicated to play a pivotal role also in the development of atherosclerotic lesions, we postulated that Nrf2 would be protective against atherosclerosis. As the role of Nrf2 in atherogenesis and plaque composition has remained unclear, we aimed to investigate the effect of global Nrf2 deficiency on the development of atherosclerotic lesions, plaque phenotype and circulating lipid levels using two different mouse models, which mimic more closely human hypercholesterolaemia and atherogenesis in comparison to ApoE -/-mice. 28 
Measurements of atherosclerosis and plaque morphology
The mice were euthanized by CO 2 inhalation and perfused with phosphate buffered saline. For analysis of atherosclerosis, aortic root and brachiocephalic arteries were fixed in 4% paraformaldehyde (pH 7.4). Tissues were embedded in paraffin for serial cross-sectional analysis (5 mm sections, mean of 3 sections per mouse at 25 mm intervals), excluding aortas, which were prepared for en face analysis and stained with Oil Red O. Cross sections of aortic root and brachiocephalic arteries were stained with haematoxylin-eosin to quantify the average lesion area (mean of 5 sections per mouse at 25 mm intervals), which were measured with a colour image analysis system (analySIS 3.00 Software). For the analysis of macrophages in the aortic and brachiocephalic lesions, serial sections from the aortic root and brachiocephalic artery were selected, immunostained with mMQ (anti mouse macrophage, mMQ AIA31240, 1:6500, Accurate Chemical & Scientific Corp.), and positive areas were quantified with a colour image analysis system (analySIS 3.00 Software). For the analysis of smooth muscle cells in the brachiocephalic lesions, serial sections from brachiocephalic artery were stained with a aSMA (anti-alpha smooth muscle actin, ab15267, Abcam) and SMHC (anti-smooth muscle myosin heavy chain, ab53219, Abcam) primary antibodies and positive areas were measured. In addition, brachiocephalic artery sections were stained with a MCP-1 (rabbit-anti mouse, ab7020, Abcam) and TNFa (rabbit-anti mouse, ab6671, Abcam) primary antibody to measure plaque inflammation, and with 4-hydroxynonenal (4-HNE) (rabbit-anti mouse, LS-C68182, LSBio) and anti-nitrotyrosine (3-NT) primary antibody (rabbit-anti mouse, 06-284, Merck Millipore) as a measure of oxidative stress.
Aortic plaque necrosis was measured from haematoxylin-and eosinstained sections and brachiocephalic artery necrosis from Masson trichrome-stained sections. Plaque necrosis was measured by morphological criteria in which plaque cholesterol clefts, lipid droplets, and acellular areas were regarded as necrotic areas. Moreover, to quantify fibrous cap thickness from brachiocephalic arteries, three serial sections per mouse were stained with Masson's Trichrome. In every section, three to five of the thinnest caps were selected, and the average was calculated. All the previous measurements were done with a colour image analysis system (analySIS 3.00 Software). Furthermore, fibrous cap thickness was analysed in relation to necrotic core area to measure cap to core ration (mm/mm 2 ). In addition, to analyse plaque calcification, aortic and brachiocephalic sections were stained with Alizarin Red S, which stains calcific depositions with red colour, which was quantified. Brachiocephalic sections were stained with Movat Pentachrome, which stains elastic and reticular fibres, collagen and mucin, to detect fibro fatty nodule area with the colour image analysis system (analySIS 3.00 Software). Moreover, to detect brachiocephalic plaque collagen content, arterial cross sections were stained with Sirius Red S protocol and collagen was quantified with the Image J 1.48V Software based on threshold and represented in relation to total plaque area. Finally, macrophage area, necrotic area, collagen content, and smooth muscle cell content were used to measure plaque instability index from brachiocephalic artery plaques as follows: (macrophages% þ necrotic area%)/(collagen% þ smooth muscle cells%) = instability index. [29] [30] [31] Quantification of plaque morphology was done in relation to total plaque area with Image J 1.48V Software based on threshold unless otherwise stated. All analyses were done in a blinded manner.
Analysis of body fat composition
Organ weights were determined for 6-month-old female LDLR ApoB 100/100 (n = 4) female mice at the age of 6 months using magnetic resonance imaging. For the imaging, the mice were anaesthetized with isoflurane inhalation (4% for induction and $1.5% during imaging). The mouse was placed on a holder, and a pneumatic pillow was placed under the mouse for respiration monitoring and gating. A 9.4 T horizontal scanner equipped with Agilent Direct Drive console (Agilent Corp., Palo Alto, CA, USA) with a quadrature volume coil with inner diameter 63 mm (Varian, Palo Alto, CA, USA) was used for transmitting and receiving the imaging signal. A 3D chemical-shift-selective gradient echo sequence with respiration gating was used to acquire interleaved fat and water images used for calculation of the fat quantity as previously described. 32 Parameters used for imaging were: rep- 
Analysis of plasma lipid profile and inflammatory cytokines
After an overnight 12 h fasting-period, $100 lL blood was drawn from the saphenous vein of LDLR -/-and Nrf2 female and male mice at the age of 6 or 12 months on a regular chow diet. Plasma was isolated by centrifugation at 4 C, 1700 Â g for 15 min and stored at -80 C for further analysis. Plasma triglycerides were analysed using the Triglycerides GPO-PAP-kit (Roche Diagnostics), total cholesterol using the Cholesterol CHOD-PAP kit (Roche Diagnostics). Plasma pro-inflammatory cytokines were analysed using BD TM Cytometric Bead Array (CBA) kit according to the manufacturer's instructions. The samples were run on FACS Calibur flow cytometer (BD Biosciences), and the results were analysed using FCAP Array 2.0.0 software (Soft Flow Hungary Ltd, Pecs, Hungary).
Echocardiography
Echocardiography was performed for LDLR -/-ApoB 100/100 (n = 4) and Nrf2
ApoB 100/100 (n = 7) female mice at the age of 6 using Vevo V R 2100 Ultrasound System (Fujifilm Visual Sonics V R ). In brief, mice were kept fully anaesthesized with 2% isoflurane inhalation. Heart rates were $500 b.p.m. in controls and in atherosclerotic mice. Standard M-mode measurements of the left ventricle dimensions, left ventricle mass and volume, ejection fraction (calculated with Teicholz formula), and stroke volume were measured in parasternal short-axis view as described earlier in reference. 33 
Isolation of bone marrow-derived macrophages

Gene expression analysis
Bone marrow-derived macrophages were cultured on 6-well plates and starved for 4 h in Optimem (Gibco V R ) with 10% LPDS and 1% P/S, then they were incubated for further 16 h at þ37 C either in the absence or presence of acetylated LDL (AcLDL) (50 mg protein/mL) or LPS from Escherichia coli (Sigma-Aldrich V R 10 ng/mL). RNA was extracted by using NucleoZOL 
Statistical analyses
Data normal distribution was tested by the Shapiro-Wilk test and to evaluate statistical significance (P < 0.05), unpaired two-tailed Student's t-test or logrank test were used. Numerical values for each measurement are shown as mean ± SEM. All statistical analyses were performed using GraphPad Prism 
Results
Nrf2 deficiency impairs development of diet-induced atherosclerosis in LDLR
À/À male and female mice
To determine the role of Nrf2 in atherogenesis, mice lacking Nrf2 in atherosclerosis-prone LDLR -/-background were subjected to a Figure 1A ). In addition, the lesion area of the entire aorta was reduced in Nrf2
-/-LDLR -/-male mice after 12 weeks of HFD ( Figure   1B ). In females, the effect was less pronounced, as the difference of the cross-sectional lesion area between LDLR -/-and Nrf2 Figure S2A ). However, the aortic root lesion area was reduced by $30% in female Nrf2
-/-LDLR -/-ApoB 100/100 mice at the age of 6 months ( Figure 3A) . After 12 months, the loss of Nrf2 decreased the lesional coverage by $65% in en face analysis of descending aortas ( Figure 3B ), whereas the difference between the two groups was not statistically significant at the level of aortic root ( Figure 3A) . cap covering the necrotic core. Characterization of plaque composition showed that macrophage positive area relative to lesion area was equal in both groups at the age of 6 and 12 months ( Figure 4A) . However, the necrotic core area was increased by $90% in Nrf2 Figure 4C ). There was no measurable calcification in aortic root plaques at the age of 6 months (Supplementary material online, Figure S2B ). Moreover, Nrf2 deficiency increased positive staining area of 4-HNE, an aldehyde produced during lipid peroxidation that reflects ROS generation at the age of 6 months ( Figure 4D ). Table 1) . Nrf2-deficiency reduced body weight also in LDLR -/-ApoB 100/100 females at the age of 6 months on a regular chow diet ( Table 2 ). In addition, the body fat content and amount of epididymal fat were reduced in Nrf2 Figure S3A ,B). Supporting systemic effects on lipid metabolism, Nrf2 deficiency significantly reduced plasma total cholesterol after 6 weeks of HFD in LDLR -/-mice, but the difference disappeared after 12 weeks of HFD ( Table 1) . Nrf2 deficiency did not change plasma triglycerides after 6 weeks of HFD, but there was a Nrf2 deficiency had no effect on plasma total cholesterol, but it reduced plasma triglycerides significantly by $20% at both 6 and 12 months of age ( Table 2) . However, Nrf2
Nrf2 deficiency lowers plasma total cholesterol in LDLR
-/-LDLR -/-ApoB 100/100 males had lower plasma total cholesterol at the age of 12 months in comparison to LDLR -/-ApoB 100/100 males, but triglyceride levels did not differ between the genotypes at any age in males ( Table 2 ). female mice were aged for atherosclerosis experiments, we observed that $36% of the Nrf2-deficient female mice (19/53) displayed weakness to an extent that required the mice be euthanized or died suddenly between the age of 5 to 12 months (P < 0.05) ( Figure 5A ). The mice in a weak condition showed variable symptoms, such as remarkable lowering in body weight (30-45% reduction), hypothermia, dyspnoea, or lower consciousness. Post-mortem dissection revealed spontaneous MIs (10/ 53) with respective dilation of the heart ventricles and pulmonary oedema (P < 0.05 in comparison to LDLR -/-ApoB 100/100 female mice) ( Figure 5A ). While in most cases mice died suddenly or had to be euthanized for ethical reasons without further study, we were able to image MI by echocardiography from a Nrf2 of control female mice displayed weakness to an extent that required the mice be euthanized or died suddenly (7/44) mainly at the age of 10-12 months, but did not show macroscopically or microscopically noticeable findings that would explain the death. Figure S4A -D).
Nrf2 deficiency predisposes to MI and sudden death in LDLR
Nrf2 deficiency promotes plaque instability in aged LDLR
À/À ApoB 100/100 female mice
In mouse models of atherosclerosis, brachiocephalic artery typically shows a complex plaque morphology that mimics human-like ruptureprone plaque morphology. 36, 37 Thus, we analysed the plaque phenotype more closely in brachiocephalic arteries and found that lesion morphology was very complex in both LDLR Figure S2C ). Plaque stability was defined as the thickness of fibrous cap that separates a necrotic core of an atherosclerotic plaque from the lumen. Interestingly, fibrous cap thickness was reduced by more than 30% in Nrf2-deficient LDLR -/-ApoB 100/100 mice ( Figure 6G) 
Nrf2 deficiency promotes plaque inflammation and oxidative stress
Since persistent systemic and local plaque chronic inflammation predisposes to plaque maturation, we next examined MCP-1 and TNFa expression in brachiocephalic arteries and found that MCP-1 positive staining area ( Figure 7A ) was increased in Nrf2 Figure 7C) Male n 5 12 Male n 5 9 Male n 5 7 Male n 5 13 Female n 5 7
Female n Figure 7D ) IL-1b ( Figure 7E) , and IL-6 ( Figure 7F ) upon stimulation by LPS or AcLDL. Moreover, plasma pro-inflammatory cytokines MCP-1 and TNFa were measured ( Figure 7H ), but found not to be different between the study groups, likely because of high variation between the individual mice. In addition to inflammatory factors, we also measured plaque oxidative stress by staining the brachiocephalic sections with 4-HNE and 3-NT primary antibodies. Nrf2 deficiency increased 4-HNE positive staining ( Figure 7I ), but 3-NT staining ( Figure 7J ) was no different between the groups.
TNF-a (
Discussion
Oxidative stress has been implicated in the initiation and progression of atherosclerosis from the early fatty streak lesions to the rupture and thrombosis of advanced atherosclerotic plaque. 1 Given that the redoxactivated transcription factor Nrf2 is a ubiquitous factor affecting the gene expression of a vast number of genes mediating antioxidant protection and suppression of inflammation, it is logical to postulate that the loss of Nrf2 aggravates atherogenesis. 11 Nevertheless, several investigators have shown that the global loss of Nrf2 alleviates atherosclerosis in ApoE -/-hypercholesterolaemic mice. [17] [18] [19] [20] Due to the limitations of ApoE -/-mice to model human atherosclerosis, we used two alternative mouse models, LDLR -/-mice fed a HFD as well as chow-fed LDLR -/ -ApoB 100/100 mice that have a lipoprotein profile characteristic of human hypercholesterolaemia, to study the effect of global loss of Nrf2 on atherogenesis. 21, 35 We discovered that Nrf2 deficiency decreased the extent of atherosclerosis measured by en face analysis as well as the size of atherosclerotic plaques in both mouse models. In a more human-like hypercholesterolaemic LDLR -/-ApoB 100/100 female mice, it also promoted plaque inflammation and oxidative stress that possibly led to an increased plaque instability, which is considered as a risk factor of MI and sudden death in humans. While the previous reports have uniformly concluded that the global loss of Nrf2 results in the reduction of atherosclerotic lesion size in ApoE -/-mice, the postulated mechanisms vary from one study to another. The proposed mechanisms include decreased CD36 expression and hence reduced uptake of modified LDL, 17,18 attenuated cholesterol crystal-induced inflammasome activation 19 as well as systemic effects via lowered plasma and liver cholesterol levels and reduced expression of lipogenic genes in the liver. 18 Given the differences in experimental design, it is hard to compare previous studies. For instance, two different Nrf2-deficient mouse strains were used, and the duration of diet, cholesterol content and age of euthanasia varied considerably. [17] [18] [19] Our study supports systemic metabolic effects of Nrf2 in high fat-fed LDLR -/-
Nrf2
-/-mice. We show reduction in the size of atherosclerotic plaques, most likely because of decreased plasma cholesterol. The connection between Nrf2 and lipid biosynthesis has been observed, as two microarray analyses using gene modified mice indicated that Nrf2 regulates the expression of several genes involved in the regulation of fatty acid and cholesterol synthesis in the liver. 39, 40 Additionally, in support of favourable metabolic effects, we found that Nrf2 deficiency reduced body weight of LDLR -/-mice on both regular chow and HFD. This is in line with previous studies, in which Nrf2 deficiency was protective against HFD induced weight gain via inhibition of adipogenesis due to impaired PPARc signalling, and an increase in energy expenditure by increased UCP-1 expression in the liver and white adipose tissue. 41, 42 It is known that murine models display sexual dimorphism in many hepatic genes involved in lipid metabolism and atherogenesis. This may well explain the differential effects in plasma lipids and atherosclerosis development between sexes in the present study.
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Nrf2 has well known anti-inflammatory functions both in vitro as well as in vivo in mouse models of inflammation. 44 We and others have shown that Nrf2 and its target genes have local anti-atherogenic effects in the vascular wall, including endothelial cells and macrophages. 11, 12, 38 Haematopoietic cell-specific Nrf2 deficiency aggravates inflammation and accelerates atherogenesis in both early 11 In summary, our results demonstrate that whole body Nrf2 deficiency delays atherogenesis measured by the size of atherosclerotic plaques but that it also promotes plaque instability in later stages of the disease. This study highlights differences between mouse models of atherosclerosis and the need for a variety of models to tease out phenotypic differences. Given that Nrf2 activators are under active drug development or already in clinical use (dimethyl fumarate, Tecfidera V R for multiple sclerosis), it is of utmost importance to clarify the role of Nrf2 in cardiometabolic diseases. This is especially relevant as these drugs are intended for long-term use also in younger subjects and therefore any adverse health effects should be closely monitored. At this juncture, it is important to note that the Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes (BEACON), trial was prematurely terminated after preliminary analyses showed that patients randomized to bardoxolone methyl experienced significantly higher rates of heart failure events. However, it was suggested that these effects we mediated by the interference with the endothelin system. 50 There is no data suggesting that Nrf2 activators would aggravate atherogenesis in humans, but longer follow-up times are necessary to draw any definite conclusions. Moreover, further studies utilizing tissuespecific gene modified mice are warranted in order to define the contribution of Nrf2 in different tissues and cell types on the atherogenic process. ApoB 100/100 mice (n = 6-9) (red dots) were sacrificed at the age of 12 months, and plaque compositions were analysed from the brachiocephalic artery. Characteristics of instable plaque, such as (A) macrophage area stained with representative pictures of mMQ stained sections, (B) necrotic core area analysed from Masson Trichrome stained sections, and (C) fibrofatty nodule area (outlined with a dotted line) were analysed from Movat's Pentachrome staining, and all the quantifications were normalized to total lesion area, with representative pictures. (D) Plaque calcification (%) was analysed from Alizarin Red S stained sections (black arrows depict red-stained calcification) in relation to total lesion area with representative pictures. Characteristics of stabile plaque, such as (E) plaque collagen content was evaluated from Picro Sirius Red staining and (F) smooth muscle cell content from aSMA stained sections in relation to plaque area with representative pictures. (G) The fibrous cap thickness (mm), was measured from Masso ns Trichrome stained sections, with representative pictures from thinned cap (indicated by black arrows). (H) Plaque instability index and (I) cap to core ratio were calculated as based on plaque morphological analysis, described more in detail in Methods section. Representative pictures are shown with a scale bar 100 lm. Each dot represents one mouse and the horizontal line represents mean ± SEM. *P < 0.05, *P < 0.05, **P < 0.01, ***P < 0.001 by the Student's t-test. 
Supplementary material
Supplementary material is available at Cardiovascular Research online. Each dot represents one mouse, and the horizontal line represents mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001 by the Student's t-test.
